<DOC>
	<DOCNO>NCT02028780</DOCNO>
	<brief_summary>The primary objective investigate safety , tolerability pharmacokinetics BI 655075 follow intravenous administration single rise dos BI 655075 administer alone administration dabigatran .</brief_summary>
	<brief_title>Study Evaluate Safety , Pharmacokinetics Pharmacodynamics BI 655075 ( Idarucizumab ) Administered Alone With Dabigatran Etexilate Japanese Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy Japanese male subject Exclusion criterion : 1 . Any relevant deviation healthy condition</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>